Early use of ACE inhibitors in the treatment of acute myocardial infarction in the united states: Experience from the National Registry of Myocardial Infarction 2

American Journal of Cardiology

Volumn 84, Issue 10, 1999, Pages 1176-1181

  Michaels, Andrew D ^a   Maynard, Charles ^b   Every, Nathan R ^b   Barron, Hal V ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; HEPARIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLINICAL TRIALS; FEMALE; HEART FAILURE, CONGESTIVE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PHYSICIAN'S PRACTICE PATTERNS; REGISTRIES; SURVIVAL ANALYSIS; THROMBOLYTIC THERAPY; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 0032726892     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00530-5     Document Type: Article

References (28)

1. Pfeffer M.A., Pfeffer J.M., Steinberg C., Finn P. Survival after an experimental myocardial infarction beneficial effects of long-term therapy with captopril . Circulation. 72:1985;406-412.
2. Pfeffer M.A., Lamas G.A., Vaughan D.E., Parisi A.F., Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med. 319:1988;80-86.
3. Pfeffer M.A., Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 81:1990;1161-1172.
4. Pfeffer M.A., Braunwald E., Moyé L.A., Basta L., Brown E.J., Cuddy T.E., Davis B.R., Geltman E.M., Goldman S., Flaker G.C., Klein M., Lamas G.A., Packer M., Rouleau J.L., Rouleau J.L., Rutherford J., Wertheimer J.H., Hawkins C.M. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 327:1992;669-677.
5. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 342:1993;821-828.
6. Køber L., Torp-Pedersen C., Carlsen J.E., Bagger H., Eliasen P., Lyngborg K., Videbek J., Cole D.S., Auclert L., Pauly N.C., Aliot E., Persson S., Camm A. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 333:1995;1670-1676.
7. Swedberg K., Held P., Kjekshus J., Rasmussen K., Ryden L., Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med. 327:1992;678-684.
8. GISSI-3 effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction . Lancet. 343:1994;1115-1122.
9. ISIS-4 a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction . Lancet. 345:1995;669-685.
10. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction interim report from the Chinese Cardiac Study (CCS-1) . Lancet. 345:1995;686-687.
11. Ambrosioni E., Borghi C., Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med. 332:1995;80-85.
12. Indications for ACE inhibitors in the early treatment of acute myocardial infarction systematic overview of individual data from 100 000 patients in randomized trials . Circulation. 97:1998;2202-2212.
13. Ryan T.J., Anderson J.L., Antman E.M., Braniff B.A., Brooks N.H., Califf R.M., Hillis L.D., Hiratzka L.F., Rapaport E., Riegel B.J., Russell R.O., Smith E.E., Weaver W.D. ACC/AHA guidelines for the management of patients with acute myocardial infarction a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Management of Acute Myocardial Infarction) . J Am Coll Cardiol. 28:1996;1328-1428.
14. Hennekens C.H., Albert C.M., Godfried S.L., Gaziano J.M., Buring J.E. Adjunctive drug therapy of acute myocardial infarction - evidence from clinical trials. N Engl J Med. 335:1996;1660-1667.
15. Every N.R., Frederick P., Robinson M., Maynard C., Bowlby L., Barron H.V. Internal validity of AMI databases a comparison of the NRMI-2 and CCP databases . (abstr) J Am Coll Cardiol. 31:1998;173A.
16. Barron H.V., Bowlby L.J., Breen T., Rogers W.J., Canto J.G., Zhang Y., Tiefenbrunn A.J., Weaver W.D. Use of reperfusion therapy for acute myocardial infarction in the United States data from the National Registry of Myocardial Infarction 2 . Circulation. 97:1998;1150-1156.
17. Gurwitz J.H., Gore J.M., Goldberg R.J., Rubison M., Chandra N., Rogers W.J. Recent age-related trends in the use of thrombolytic therapy in patients who have had acute myocardial infarction. National Registry of Myocardial Infarction. Ann Intern Med. 124:1996;283-291.
18. McLaughlin T.J., Soumerai S.B., Willison D.J., Gurwitz J.H., Borbas C., Guadagnoli E., McLaughlin B., Morris N., Cheng S.C., Hauptman P.J., Antman E., Casey L., Asinger R., Gobel F. Adherence to national guidelines for drug treatment of suspected acute myocardial infarction evidence for undertreatment in women and the elderly . Arch Intern Med. 156:1996;799-805.
19. Soumerai S.B., McLaughlin T.J., Spiegelman D., Hertzmark E., Thibault G., Goldman L. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA. 277:1997;115-121.
20. Barron H.V., Viskin S., Lundstrom R.J., Swain B.E., Truman A.F., Wong C.C., Selby J.V. Beta-blocker dosages and mortality after myocardial infarction data from a large health maintenance organization . Arch Intern Med. 158:1998;449-453.
21. Barron H.V., Michaels A.D., Maynard C., Every N.R. Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States data from the National Registry of Myocardial Infarction 2 . J Am Coll Cardiol. 32:1998;360-367.
22. Bjorck S., Mulec H., Johnsen S.A., Norden G., Aurell M. Renal protective effect of enalapril in diabetic nephropathy. Br Med J. 304:1992;339-343.
23. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 329:1993;1456-1462.
24. Ravid M., Lang R., Rachmani R., Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med. 156:1996;286-289.
25. Pfeffer M.A., Greaves S.C., Arnold M.O., Glynn R.J., LaMotte F.S., Lee R.T., Menapace F.J., Rapaport E., Ridker P.M., Rouleau J.L., Solomon S.D., Hennekens C.H. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction the Healing and Early Afterload Reducing Therapy Trial . Circulation. 95:1996;2643-2651.
26. Rogers W.J., Bowlby L.J., Chandra N.C., French W.J., Gore J.M., Lambrew C.T., Rubison R.M., Tiefenbrunn A.J., Weaver W.D. Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction. Circulation. 90:1994;2103-2114.
27. Kjekshus J., Swedberg K. Tolerability of enalapril in congestive heart failure. Am J Cardiol. 62:(suppl):1988;67A-72A.
28. Krumholz H.M., Vaccarino V., Ellerbeck E.F., Kiefe C., Hennen J., Kresowik T.F., Gold J.A., Jencks S.F., Radford M.J. Determinants of appropriate use of angiotensin-converting enzyme inhibitors after acute myocardial infarction in persons ≥65 years of age. Am J Cardiol. 79:1997;581-586.